Characterization of the interaction between the chlamydial adhesin omcb and the human host cell

Journal of Bacteriology

Volumn 195, Issue 23, 2013, Pages 5323-5333

  Fechtner, Tim ^a   Stallmann, Sonja ^a   Moelleken, Katja ^a   Meyer, Klaus L ^a   Hegemann, Johannes H ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ARGININE; BACTERIAL PROTEIN; BACTERIAL PROTEIN OMCB; HEPARAN SULFATE; HEPARIN; NEUTRALIZING ANTIBODY; PROLINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ADHERENCE; CARBOXY TERMINAL SEQUENCE; CELL INTERACTION; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HOST CELL; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; SEROTYPE;

ADHESINS, BACTERIAL; ANIMALS; BACTERIAL ADHESION; BACTERIAL OUTER MEMBRANE PROTEINS; CHLAMYDOPHILA PNEUMONIAE; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; HEP G2 CELLS; HUMANS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84887530763     PISSN: 00219193     EISSN: 10985530     Source Type: Journal    
DOI: 10.1128/JB.00780-13     Document Type: Article

References (51)

1. Kuo CC, Jackson LA, Campbell LA, Grayston JT. 1995. Chlamydia pneumoniae (TWAR). Clin. Microbiol. Rev. 8:451-461.
2. Blasi F, Tarsia P, Aliberti S. 2009. Chlamydophila pneumoniae. Clin. Microbiol. Infect. 15:29-35.
3. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, Wang SP. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625.
4. Whitcher JP, Srinivasan M, Upadhyay MP. 2001. Corneal blindness: a global perspective. Bull. World Health Organ. 79:214-221.
5. Bebear C, de Barbeyrac B. 2009. Genital Chlamydia trachomatis infections. Clin. Microbiol. Infect. 15:4-10.
6. Abdelrahman YM, Belland RJ. 2005. The chlamydial developmental cycle. FEMS Microbiol. Rev. 29:949-959.
7. Carabeo RA, Hackstadt T. 2001. Isolation and characterization of a mutant Chinese hamster ovary cell line that is resistant to Chlamydia trachomatis infection at a novel step in the attachment process. Infect. Immun. 69:5899-5904.
8. Ting LM, Hsia RC, Haidaris CG, Bavoil PM. 1995. Interaction of outer envelope proteins of Chlamydia psittaci GPIC with the HeLa cell surface. Infect. Immun. 63:3600-3608.
9. Mygind P, Christiansen G, Birkelund S. 1998. Topological analysis of Chlamydia trachomatis L2 outer membrane protein 2. J. Bacteriol. 180:5784-5787.
10. Stephens RS, Koshiyama K, Lewis E, Kubo A. 2001. Heparin-binding outer membrane protein of chlamydiae. Mol. Microbiol. 40:691-699.
11. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, Mariani M, Manetti R, Agnusdei M, Cevenini R, Donati M, Nogarotto R, Norais N, Garaguso I, Nuti S, Saletti G, Rosa D, Ratti G, Grandi G. 2002. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70:368-379.
12. Fadel S, Eley A. 2007. Chlamydia trachomatis OmcB protein is a surfaceexposed glycosaminoglycan-dependent adhesin. J. Med. Microbiol. 56:15-22.
13. Moelleken K, Hegemann JH. 2008. The Chlamydia outer membrane protein OmcB is required for adhesion and exhibits biovar-specific differences in glycosaminoglycan binding. Mol. Microbiol. 67:403-419.
14. Chen JC, Stephens RS. 1994. Trachoma and LGV biovars of Chlamydia trachomatis share the same glycosaminoglycan-dependent mechanism for infection of eukaryotic cells. Mol. Microbiol. 11:501-507.
15. Chen JC, Zhang JP, Stephens RS. 1996. Structural requirements of heparin binding to Chlamydia trachomatis. J. Biol. Chem. 271:11134-11140.
16. Chen JCR, Stephens RS. 1997. Chlamydia trachomatis glycosaminoglycan dependent and independent attachment to eukaryotic cells. Microb. Pathog. 22(1):23-30.
17. Zaretzky FR, Pearce-Pratt R, Phillips DM. 1995. Sulfated polyanions block Chlamydia trachomatis infection of cervix-derived human epithelia. Infect. Immun. 63:3520-3526.
18. Davis CH, Wyrick PB. 1997. Differences in the association of Chlamydia trachomatis serovar E and serovar L2 with epithelial cells in vitro may reflect biological differences in vivo. Infect. Immun. 65:2914-2924.
19. Taraktchoglou M, Pacey AA, Turnbull JE, Eley A. 2001. Infectivity of Chlamydia trachomatis serovar LGV but not E is dependent on host cell heparan sulfate. Infect. Immun. 69:968-976.
20. Wuppermann FN, Hegemann JH, Jantos CA. 2001. Heparan sulfate-like glycosaminoglycan is a cellular receptor for Chlamydia pneumoniae. J. Infect. Dis. 184:181-187.
21. Yabushita H, Noguchi Y, Habuchi H, Ashikari S, Nakabe K, Fujita M, Noguchi M, Esko JD, Kimata K. 2002. Effects of chemically modified heparin on Chlamydia trachomatis serovar L2 infection of eukaryotic cells in culture. Glycobiology 12:345-351.
22. Yan Y, Silvennoinen-Kassinen S, Leinonen M, Saikku P. 2006. Inhibitory effect of heparan sulfate-like glycosaminoglycans on the infectivity of Chlamydia pneumoniae in HL cells varies between strains. Microbes Infect. 8:866-872.
23. Kjellen L, Lindahl U. 1991. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60:443-475.
24. Capila I, Linhardt RJ. 2002. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl. 41:391-412.
25. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:729-777.
26. Smits NC, Shworak NW, Dekhuijzen PN, van Kuppevelt TH. 2010. Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema. Anat. Rec. (Hoboken) 293:955-967.
27. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156-167.
28. Cardin AD, Weintraub HJ. 1989. Molecular modeling of proteinglycosaminoglycan interactions. Arteriosclerosis 9:21-32.
29. Everett KD, Hatch TP. 1995. Architecture of the cell envelope of Chlamydia psittaci 6BC. J. Bacteriol. 177:877-882.
30. Zhang JP, Stephens RS. 1992. Mechanism of C. trachomatis attachment to eukaryotic host cells. Cell 69:861-869.
31. Beswick EJ, Travelstead A, Cooper MD. 2003. Comparative studies of glycosaminoglycan involvement in Chlamydia pneumoniae and C. trachomatis invasion of host cells. J. Infect. Dis. 187:1291-1300.
32. Fadel S, Eley A. 2008. Differential glycosaminoglycan binding of Chlamydia trachomatis OmcB protein from serovars E and LGV. J. Med. Microbiol. 57:1058-1061.
33. Dersch P, Isberg RR. 1999. A region of the Yersinia pseudotuberculosis invasin protein enhances integrin-mediated uptake into mammalian cells and promotes self-association. EMBO J. 18:1199-1213.
34. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, van Kuppevelt TH. 2002. Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J. Biol. Chem. 277:10982-10986.
35. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH. 1998. Generation and application of type-specific antiheparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J. Biol. Chem. 273:12960-12966.
36. Ten Dam GB, Kurup S, van de Westerlo EM, Versteeg EM, Lindahl U, Spillmann D, van Kuppevelt TH. 2006. 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J. Biol. Chem. 281:4654-4662.
37. Smits NC, Robbesom AA, Versteeg EM, van de Westerlo EM, Dekhuijzen PN, van Kuppevelt TH. 2004. Heterogeneity of heparan sulfates in human lung. Am. J. Respir. Cell Mol. Biol. 30:166-173.
38. Combet C, Blanchet C, Geourjon C, Deleage G. 2000. NPS@: network protein sequence analysis. Trends Biochem. Sci. 25:147-150.
39. Margalit H, Fischer N, Ben-Sasson SA. 1993. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J. Biol. Chem. 268:19228-19231.
40. Jenniskens GJ, Oosterhof A, Brandwijk R, Veerkamp JH, van Kuppevelt TH. 2000. Heparan sulfate heterogeneity in skeletal muscle basal lamina: demonstration by phage display-derived antibodies. J. Neurosci. 20:4099-4111.
41. Wijnhoven TJ, van de Westerlo EM, Smits NC, Lensen JF, Rops AL, van der Vlag J, Berden JH, van den Heuvel LP, van Kuppevelt TH. 2008. Characterization of anticoagulant heparinoids by immunoprofiling. Glycoconj. J. 25:177-185.
42. Christianson HC, van Kuppevelt TH, Belting M. 2012. ScFv antiheparan sulfate antibodies unexpectedly activate endothelial and cancer cells through p38 MAPK: implications for antibody-based targeting of heparan sulfate proteoglycans in cancer. PLoS One 7:e49092. doi:10.1371/journal.pone.0049092.
43. Kurup S, Wijnhoven TJ, Jenniskens GJ, Kimata K, Habuchi H, Li JP, Lindahl U, van Kuppevelt TH, Spillmann D. 2007. Characterization of anti-heparan sulfate phage display antibodies AO4B08 and HS4E4. J. Biol. Chem. 282:21032-21042.
44. Suchland RJ, Eckert LO, Hawes SE, Stamm WE. 2003. Longitudinal assessment of infecting serovars of Chlamydia trachomatis in Seattle public health clinics: 1988-1996. Sex Transm. Dis. 30:357-361.
45. Morre SA, Rozendaal L, van Valkengoed IG, Boeke AJ, van Voorst Vader PC, Schirm J, de Blok S, van Den Hoek JA, van Doornum GJ, Meijer CJ, van Den Brule AJ. 2000. Urogenital Chlamydia trachomatis serovars in men and women with a symptomatic or asymptomatic infection: an association with clinical manifestations? J. Clin. Microbiol. 38:2292-2296.
46. Lysen M, Osterlund A, Rubin CJ, Persson T, Persson I, Herrmann B. 2004. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish county. J. Clin. Microbiol. 42:1641-1647.
47. Yang B, Zheng HP, Feng ZQ, Xue YH, Wu XZ, Huang JM, Xue XJ, Jiang HN. 2010. The prevalence and distribution of Chlamydia trachomatis genotypes among sexually transmitted disease clinic patients in Guangzhou, China, 2005-2008. Jpn. J. Infect. Dis. 63:342-345.
48. Kim JH, Chan C, Elwell C, Singer MS, Dierks T, Lemjabbar-Alaoui H, Rosen SD, Engel JN. 2013. Endosulfatases SULF1 and SULF2 limit Chlamydia muridarum infection. Cell Microbiol. 15:1560-1571.
49. Hultgren SJ, Normark S, Abraham SN. 1991. Chaperone-assisted assembly and molecular architecture of adhesive pili. Annu. Rev. Microbiol. 45:383-415.
50. Wijnhoven TJ, Lensen JF, Rops AL, van der Vlag J, Kolset SO, Bangstad HJ, Pfeffer P, van den Hoven MJ, Berden JH, van den Heuvel LP, van Kuppevelt TH. 2006. Aberrant heparan sulfate profile in the human diabetic kidney offers new clues for therapeutic glycomimetics. Am. J. Kidney Dis. 48:250-261.
51. Smetsers TF, van de Westerlo EM, ten Dam GB, Overes IM, Schalkwijk J, van Muijen GN, van Kuppevelt TH. 2004. Human singlechain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J. Investig. Dermatol. 122:707-716.